Profile data is unavailable for this security.
About the company
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
- Revenue in EUR (TTM)1.25bn
- Net income in EUR121.30m
- Incorporated1984
- Employees5.46k
- LocationVirbac SA13eme rue LID, Bp 27, Carros CedexCARROS 06510FranceFRA
- Phone+33 492087100
- Fax+33 492087165
- Websitehttps://corporate.virbac.com/
More ▼
Mergers & acquisitions
| Acquired company | VIRP:PAR since announced | Transaction value |
|---|---|---|
| Sasaeah Holdings Co Ltd | 6.29% | 303.94m |
Data delayed at least 15 minutes, as of Jul 22 2024 16:35 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA Biologics Inc | 260.30m | -3.35m | 2.83bn | 624.00 | -- | 20.04 | 646.01 | 10.88 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Xiamen Amoytop Biotech Co Ltd | 281.50m | 75.88m | 2.89bn | 1.96k | 38.10 | 11.40 | -- | 10.27 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Virbac SA | 1.25bn | 121.30m | 2.96bn | 5.46k | 24.38 | 3.25 | 17.60 | 2.37 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
| Hypera SA | 1.32bn | 280.03m | 2.99bn | 9.00k | 10.78 | 1.56 | 9.33 | 2.27 | 2.67 | 2.67 | 12.60 | 18.50 | 0.3366 | 1.34 | 3.19 | -- | 7.13 | 8.29 | 8.64 | 9.98 | 62.47 | 63.49 | 21.18 | 26.01 | 1.37 | -- | 0.4798 | 50.18 | 4.88 | 16.27 | -3.30 | 7.74 | 29.83 | 10.24 |
| Twist Bioscience Corp | 255.07m | -176.61m | 3.01bn | 919.00 | -- | 5.84 | -- | 11.80 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 382.50m | 60.67m | 3.08bn | 5.10k | 51.45 | 9.60 | 40.60 | 8.05 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| HUTCHMED (China) Ltd | 770.27m | 92.64m | 3.13bn | 1.99k | 34.04 | 4.67 | 31.18 | 4.07 | 0.8974 | 0.8974 | 7.61 | 6.55 | 0.7258 | 7.19 | 7.69 | 3,292,181.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| Ajanta Pharma Ltd | 462.04m | 89.60m | 3.13bn | 7.84k | 35.27 | 8.07 | 29.99 | 6.78 | 64.79 | 64.79 | 334.10 | 283.31 | 0.9034 | 1.30 | 3.65 | 5,365,515.00 | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.22 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
Data as of Jul 22 2024. Currency figures normalised to Virbac SA's reporting currency: Euro EUR
11.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 155.98k | 1.84% |
| Grandeur Peak Global Advisors LLCas of 30 Apr 2024 | 151.75k | 1.79% |
| Oddo BHF Asset Management SASas of 28 Jun 2024 | 114.51k | 1.35% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 106.65k | 1.26% |
| Financi�re de l'�chiquier SAas of 27 Mar 2024 | 93.79k | 1.11% |
| T. Rowe Price International Ltd.as of 30 Jun 2024 | 81.75k | 0.97% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Jun 2024 | 74.41k | 0.88% |
| Lazard Fr�res Gestion SASas of 29 Dec 2023 | 71.21k | 0.84% |
| Amundi Asset Management SA (Investment Management)as of 03 Jul 2024 | 66.50k | 0.79% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 60.32k | 0.71% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
